| Literature DB >> 26912767 |
Haamid Syed1, Ghassan Bachuwa1, Sunil Upadhaya1, Firas Abed2.
Abstract
Interstitial lung disease (ILD) is a rare adverse effect of nitrofurantoin and can range from benign infiltrates to a fatal condition. Nitrofurantoin acts via inhibiting the protein synthesis in bacteria by helping reactive intermediates and is known to produce primary lung parenchymal injury through an oxidant mechanism. Stopping the drug leads to complete recovery of symptoms. In this report, we present a case of nitrofurantoin-induced ILD with the recovery of symptoms and disease process after stopping the drug. 2016 BMJ Publishing Group Ltd.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26912767 PMCID: PMC4769449 DOI: 10.1136/bcr-2015-213967
Source DB: PubMed Journal: BMJ Case Rep ISSN: 1757-790X